Preeclampsia Risk Screening Test
Screening for risk of preterm preeclampsia
Pre-clinicalActive
Key Facts
Indication
Screening for risk of preterm preeclampsia
Phase
Pre-clinical
Status
Active
Company
About Metabolomic Diagnostics
Metabolomic Diagnostics is a Cork, Ireland-based deep-tech diagnostics company founded in 2013, specializing in biomarker discovery and assay development for complex diseases, particularly in maternal health. Its proprietary platform integrates mass spectrometry multiplexing with advanced bioinformatics to develop diagnostic tests, with its lead program targeting the early screening of preterm preeclampsia. In September 2024, the company entered into an agreement to be acquired by Trinity Biotech, aiming to accelerate the commercialization of its maternal health solutions and expand its market presence.
View full company profile